Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23223763 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2EPHX1ATMPAX8GAA | |
| SCHEMBL23223762 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2EPHX1ATMPAX8GAA | |
| SCHEMBL18918566 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2EPHX1ATMPAX8GAA | |
| SCHEMBL18918531 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2EPHX1ATMPAX8GAA | |
| SCHEMBL6313513 | 0.81 | CYP3A4 (0.55) | SMN1; SMN2MAPTLMNANPC1ALDH1A1 | |
| SCHEMBL29798859 | 0.80 | NPC1 (0.58) | SMN1; SMN2EPHX1L3MBTL1NAAANPC1 | |
| SCHEMBL23223972 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2EPHX1ATMPAX8GAA | |
| SCHEMBL2276760 | 0.77 | HPGD (0.56) | SMN1; SMN2MAPTL3MBTL1UNGLMNA | |
| SCHEMBL6184692 | 0.76 | UNG (0.56) | SMN1; SMN2GAAL3MBTL1ERN1UNG | |
| SCHEMBL18259815 | 0.76 | NPC1 (0.52) | SMN1; SMN2EPHX1PAX8L3MBTL1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383867-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2021-04-14 | — | — | EP | disclosed |
| EP-3383867-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.A. (IT) | 2018-10-10 | — | — | EP | disclosed |
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| WO-2017093208-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | WO | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093208-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | WO | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | SMN1; SMN2 2776/4885EPHX1 1279/4885ATM 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.